Skip to main content

Advertisement

Fig. 1 | BMC Cancer

Fig. 1

From: Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study

Fig. 1

Progression-free survival (PFS) and overall survival (OS) analyses. a-b: PFS (a) and OS (b) for patients with and without eribulin-induced liver dysfunction (EILD) among all patients. c-d: PFS (c) and OS (d) for the patients with and without EILD among the patients without liver metastasis. e-f: PFS (e) and OS (f) for the patients with and without EILD among the patients with liver metastasis

Back to article page